AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daily Turnover | The turnover of Exact Sciences on 7/18 was $109.63 Million, Ranking 772
ByAinvest
Friday, Jul 18, 2025 6:00 pm ET1min read
The turnover of Exact Sciences on 7/18/2025 was $109.63 million, ranking 772 in today's market, the Volume is 2.15 million.
Exact Sciences(EXAS) shares closed at $50.46, down 3.35% on 7/18/2025, down 2.79% in the last 5 trading days, down 5.04% this month, down 10.20% year-to-date and up 7.80% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 7/18/2025 | $109.63 million | 2.15 million | $50.46 | -3.35% |
| 7/17/2025 | $89.10 million | 1.69 million | $52.21 | -2.72% |
| 7/16/2025 | $83.64 million | 1.57 million | $53.67 | 1.28% |
| 7/15/2025 | $140.34 million | 2.62 million | $52.99 | -2.41% |
| 7/14/2025 | $121.57 million | 2.26 million | $54.3 | 4.60% |
【Company Profile】
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer and was incorporated in the State of Delaware on February 10, 1995. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal pre-cancer and cancer. The company's primary goal is to become the market leader for a patient-friendly diagnostic screening product for the early detection of colorectal pre-cancer and cancer. The company's strategic roadmap to achieve this goal includes the following key components: advance its product through U.S. Food and Drug Administration (FDA) clinical approval process; commercialize an FDA-approved product that detects colorectal pre-cancer and cancer; and secure favorable reimbursement for its product from payors.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet